AbbVie Must Be Sent Message, Jury Told In AndroGel Trial

By Diana Novak Jones (March 22, 2018, 8:21 PM EDT) -- Attorneys for a man who suffered a heart attack while on AbbVie's AndroGel wrapped up their case Thursday, telling an Illinois federal jury that the pharmaceutical company won't change the way it sells its blockbuster testosterone replacement therapy drug unless it is sent a strong message and faces financial pressure....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!